Skip to main content

Table 2 Ten most common ART regimens purchased in 2016; n = 1524 (76.4% of the total sample of 1995 participants)

From: HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme

Regimen N = 1524 n (%)
dolutegravir/abacavir/lamivudine 419 (27.5%)
elvitegravir/cobicistat/TAF/emtricitabine 256 (16.8%)
efavirenz/TDF/emtricitabine 207 (13.6%)
rilpivirine/TDF/emtricitabine 190 (12.5%)
dolutegravir + TDF/emtricitabine 132 (8.7%)
raltegravir + TDF/emtricitabine 81 (5.3%)
nevirapine + TDF/emtricitabine 78 (5.1%)
elvitegravir/cobicistat/TDF/emtricitabine 61 (4.0%)
nevirapine + abacavir/lamivudine 59 (3.9%)
r/Atazanavir + TDF/emtricitabine 41 (2.7%)
  1. TDF tenofovir disoproxil fumarate, TAF tenfovir alafenamide